Key facts
- This page summarizes Jonathan E. Lim's Form 4 filing for Maze Therapeutics, Inc. (MAZE).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 24 Sep 2025, 16:17.
Jonathan E. Lim - 22 Sep 2025 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)
- Role
- Director
- Signature
- /s/ Courtney Phillips, as attorney-in-fact
- Issuer symbol
- MAZE
- Transactions as of
- 22 Sep 2025
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 24 Sep 2025, 16:17:21 UTC
- Previous filing
- 23 Jun 2025
- Next filing
- 30 Jan 2026
- SEC
- View on sec.gov
Key filing fact
Jonathan E. Lim filed Form 4 for Maze Therapeutics, Inc. (MAZE) on 24 Sep 2025.
Change
- Previous filing in this sequence was filed on 23 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001283290
Primary reporting owner
Lim Jonathan E
- Relationship
- Director
- Address
- C/O MAZE THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
- Signature
- /s/ Courtney Phillips, as attorney-in-fact
- Signature date
- 24 Sep 2025
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
MAZE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +18,000
- Change %
- Price
- $0.000000
- Shares after
- 18,000
- Date
- 22 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,000
- Exercise price
- $23.67
- Footnotes
- F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date. |